Staff Profile

Introduction

Professor of Experimental Cancer Therapeutics, since 2006, having worked in Newcastle since 1982. More than 30 years’ experience in the development and biological evaluation of novel drugs to treat cancer and the development of biomarkers to predict and assess their effects. Major interest is in targeting the DNA damage response see  https://en.wikipedia.org/wiki/Nicola_Curtin  

ROLES AND RESPONSIBILITIES

Team Leader: DNA damage response

Member of FMS Equality, Diversity and Inclusion Team

Former member of both Senate and Council (2015-2020)

Chair NCRI CTRad Workstream 1

QUALIFICATIONS

BA (Biology) University of York 1975

MSc Liver carcinogenesis Manchester University 1977

PhD Biochemistry of liver carcinogenesis University of Surrey 1981

PREVIOUS POSITIONS

2002-6           Senior Lecturer in Cell Biology and Experimental Therapeutics of Cancer, Northern Institute for Cancer Research, University of Newcastle upon Tyne.

1996-2002 Lecturer in Cell Biology and Experimental Therapeutics of Cancer, Cancer Research Unit, University of Newcastle upon Tyne.

1990-6         Senior Research Associate, Cancer Research Unit, University of Newcastle upon Tyne.

1985-1990    Research Associate, Cancer Research Unit. University of Newcastle upon Tyne.

1982-1985    Research Associate, Public Health Laboratories, Newcastle upon Tyne.

MEMBERSHIPS

British Association Cancer Research

American Association Cancer Research

NCRI Clinical and Translational Radiotherapy Research Working Group (CTRad)

Yorkshire Cancer Research Scientific Advisory Board

Science Foundation Ireland Scientific Advisory Board

Research Council of Norway Strategic Initiative on Cancer Research: Panel member

Council of Life Sciences of OTKA (Hungarian Scientific Research Fund)

Leukaemia and Lymphoma Research (site visit panel)

CRUK-EORTC committee on NCI compounds

RESEARCH INTERESTS

My work focusses primarily on how DNA damage is signalled to cell cycle checkpoints and DNA repair, otherwise known as the DNA damage response (DDR), and how this can be used for improved cancer therapy. The most exciting discovery from my lab was the synthetic lethality of PARP inhibitors (PARPi) in cancers lacking homologous recombination DNA repair (HRR), e.g. due to BRCA mutations. This discovery, published in 2005 in Nature has led to a major paradigm shift in the treatment of cancers and now 4 PARPi (including rucaparib, that I helped to develop from 1997 to 2010) are approved for cancer therapy.

Current Work

1.       The evaluation of drugs targeting DDR pathways: PARP, DNA-PK, ATM, ATR CHK1, Wee1

• PARP signals and promotes the repair of DNA breaks (mostly single-stranded) that are the most common form of naturally occurring DNA damage. DNA-PK signals and promotes the repair of DNA double strand breaks that are highly cytotoxic and ATM/CHK2 and ATR/CHK1/Wee1 signal DNA damage to cell cycle checkpoints so cells don’t try to replicate with damaged DNA.
• PARP inhibitors

2.       The identification and therapeutic exploitation of the dysregulation of the DNA damage response, which is a common characteristic of cancer. In particular, identifying determinants of sensitivity to drugs that target components of the DNA damage response, like PARP and ATR inhibitors that may subsequently be used to develop predictive biomarkers to stratify patients to appropriate therapy.

• The development of an assay for homologous recombination DNA repair (HRR) function that can be used on patients’ tumour cells. HRR defects are largely tumour-specific and a determinant of sensitivity to PARP inhibitors so this allow patient stratification for PARP inhibitor therapy
• Identification that common cancer-associated defects in the DNA damage response make cells more sensitive to killing with ATR inhibitors.

3.       The development of pharmacodynamic biomarkers to monitor the activity of novel drugs targeting the DNA damage response (published assays are for PARP and ATR inhibitors) that can be used in clinical trials.

Other Expertise

Antifolates, cancer metabolism, nucleoside transport

Postgraduate supervision

PhD students: 22 completed on time, 2 awarded the faculty prize, 3 ongoing

MD students: 4 completed on time, 1 ongoing

MSc Oncology (web-based learning) : Module leader of Cancer Pharmacology module

Esteem Indicators

REF impact case 2014

Prize: CR UK Translational Research Prize Nov 2010

Yorkshire Cancer Research Scientific Advisory Board

NCRI Clinical and Translational Radiotherapy Research Working Group (CTRad)

Council of Life Sciences of OTKA (Hungarian Scientific Research Fund, annually)

Science Foundation Ireland Scientific Advisory Board (occasional)

Leukaemia and Lymphoma Research (site visit panel)

Research Council of Norway Strategic Initiative on Cancer Research: Panel member (approx. biannually)

Expert Reviews in Molecular Medicine - Editor in Chief

British Journal of Pharmacology

Cancers

American Journal of Translational Research

Regular reviewer of grants proposals submitted to CRUK, MRC, Wellcome

Regular reviewer of manuscripts submitted to, Nature, Nature Medicine, Nature Reviews Cancer, Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics, Oncogene, Oncotarget

Invited Reviews: Nature Reviews Cancer, Nature Reviews Drug Discovery, Lancet Oncology

 Funding (current)

Intermittent PARP inhibitor in recurrent ovarian cancer (IPIROC). A Mukhopadhyay and NJ Curtin (Co PI) £30,000 seedcorn funding CRUK DBT/ Wellcome Trust India Alliance Affordable Approaches to Cancer

Investigating therapeutic application of PARP inhibitor as chemo-radiosensitser in cervical cancer and its effect on renal protection. NJ Curtin (PI) Academy of Medical Sciences £99,000 (2019-2021)

Increasing the therapeutic application of PARP inhibitors in ovarian cancer by inhibiting DNA repair. NJ Curtin (PI), R O’Donnell, Y Drew, A Mukhopadhyay. JGWP £49,950 (2017-2018)

Systems Medicine of Metabolic Signalling Networks: A New Concept for Breast Cancer Stratification. (K. Thedieck Co-ordinator, Groningen, Netherlands) Horizon 2020 £258,700

Investigation of the effects of DNA repair inhibitors in pre-clinical models of neuroblastomas with ATM, MYCN and TP53 abnormalities. D Tweddle and NJ Curtin co-applicants Little Princess Trust £100,000 (01/09/2017-31/08/2020)

NEOCATS – Northern nEoadjuvant Ovarian CAncer Translational Study. Y Drew, R O’Donnell and NJ Curtin Newcastle Healthcare Charity £289,163 01/03/2018-29/02/2020

Investigating BRCAness in epithelial ovarian cancer (EOC) in India to develop stratified surgical and chemotherapy options. NJ Curtin (UK PI) A Mukhopadhyay (India PI) DST-UKIERI (British Council) £78,470 April 2017-March 2021

Understanding synthetic lethality of ATR inhibitors with DDR dysregulation common in ovarian cancer. NJ Curtin (PI) Y Drew, F Zenke (Merck) £141,636 MRC Industrial CASE 1/10/2016- 25/12/2020

Funding (Previous)

Grant income for previous 10 years as PI £1,981,200 from Industry, £587,500 from Cancer Charities and £68,000 from Research Councils. Co. I. £10 million from Charities and £211,000 from Industry

Patents

1.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., and Golding, B. T.  Benzamide Analogues ADPRT (PARP) Inhibitors. Patent Application Number PCT/GB95/00513 (1995)

2.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Benzimidazole PARP Inhibitors.Patent Application Number PCT/GB96/01832.

3.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T.  Prodrugs of PARP Inhibitors.Patent Application Number PCT/GB97/02701.5

4.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Pyrimidopyrimidine Compounds.  Patent Application Number PCT/GB97/06618.7.

5.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T., Endicott, J.A., Noble, M.E.M., Boyle, F.T. and Jewsbury, P.J. Purine CDK Inhibitors. Patent Application Number PCT/GB97/14603.9

6.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Endicott, J.A., Noble, M.E.M., Boyle, F.T. and Jewsbury, P.J. Pyrimidine CDK Inhibitors. Patent Application Number PCT/GB98/06739.0

7.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Dipyridamole analogues. Patent Application Number PCT/GB98/00966

8.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. Golding, B. T., Hardcastle I, Endicott, J.A., Noble, M.E.M., Boyle, F.T. and Jewsbury, P.J. Anilinopurine CDK Inhibitors. Patent Application Number PCT/GB01/01686.4

9.       Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., Golding, B. T. Hardcastle, I.R., Martin, N., Smith, G.C.M., Raynaud, F. and Workman, P. DNA-PK inhibitors – 1 Patent Application Number PCT/GB01/19865.4 GB/14.08.01/GBA0119865.4

10.   Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., Golding, B. T. Hardcastle, I.R., Martin, N., Smith, G.C.M., Raynaud, F. and Workman, P. DNA-PK inhibitors-2. Patent Application Number PCT/GB01/19863.9

11.   Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., Golding, B. T. Hardcastle, I.R., Martin, N., Smith, G.C.M., Raynaud, F. and Workman, P. DNA-PK inhibitors-3. Patent Application Number 04014411.4

12.   Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., Golding, B. T. Hardcastle, I.R., Martin, N., Smith, G.C.M., Raynaud, F. and Workman, P. Thiopyran-4-ones as DNA-PK inhibitors. Patent Application Number PCT/GB2002/003740

13.   Helleday T and Curtin NJ. Therapeutic Compounds (PARP inhibitors in homologous repair/BRCA defective cancer) Patent Application Number PCT/GB2004/003183. Publication number WO 2005/012305 A2 Divisional application 16th April 2004 GB 0408524.7

14.   Newcastle Inventors. Calvert AH, Curtin NJ, Jones C, Newell DR, Plummer ER and Thomas HR.  Therapeutic Combinations Comprising PARP inhibitor US application No. 60/612,458 Filed 22^nd September 2004 WO/2006/033006) THERAPEUTIC COMBINATIONS COMPRISING POLY(ADP-RIBOSE) POLYMERASES INHIBITOR

15.   Falcon S, Reaper P, Pollard J, Curtin NJ, Middleton FK and Chen T. Method for measuring ATR inhibition mediated increases in DNA damage. US patent application#14/045,373

Industrial Relevance

Much of my work has been in collaboration with Pharmaceutical companies and has been financially supported by: Agouron Pharmaceuticals, Astra Zeneca, BioMarin, BiPar Sciences, Clovis, Cyclacell, Eli Lilley, KuDOS, Merck, Pfizer, and Vertex Pharmaceuticals. I consult for: Abbot, BioMarin, Eisai, Tesaro

Undergraduate Teaching

Personal Tutor

Supervisor of final year projects and Erasmus Students

Lecture on PED306

Postgraduate Teaching

MSc Oncology and Palliative Care Module leader: Pharmacology of Anticancer Drugs 

MRes Project supervisor 

• Southgate HED, Chen L, Tweddle DA, Curtin NJ. ATR inhibition potentiates parp inhibitor cytotoxicity in high risk neuroblastoma cell lines by multiple mechanisms. Cancers 2020, 12(5), 1095.
• Bradbury A, O'Donnell R, Drew Y, Curtin NJ, Sharma Saha S. Characterisation of ovarian cancer cell line NIH-OVCAR3 and implications of genomic, transcriptomic, proteomic and functional DNA damage response biomarkers for therapeutic targeting. Cancers 2020, 12(7), 1939.
• Smith HL, Southgate H, Tweddle DA, Curtin NJ. DNA damage checkpoint kinases in cancer. Expert Reviews in Molecular Medicine 2020, 22, e2.
• Smith H, Prendergast L, Curtin NJ. Exploring the synergy between PARP and CHK1 inhibition in matched BRC2 mutant and corrected cells. Cancers 2020, 12(4), 878.
• Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nature Reviews Drug Discovery 2020, 19(10), 711-736.
• Curtin N, Banyai K, Thaventhiran J, Le Quesne J, Helyes Z, Bai P. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?. British Journal of Pharmacology 2020, 177(16), 3635-3645.
• Bradbury A, Hall S, Curtin N, Drew Y. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?. Pharmacology and Therapeutics 2020, 207, 107450.
• Southgate HED, Chen L, Curtin NJ, Tweddle DA. Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma. Frontiers in Oncology 2020, 10, 371.
• Curtin NJ. The development of Rucaparib/Rubraca(R): a story of the synergy between science and serendipity. Cancers 2020, 12(3), 564.
• Mukhopadhyay A, Drew Y, Matheson E, Salehan M, Gentles L, Pachter JA, Curtin NJ. Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors. Biochemical Pharmacology 2019, 167, 125-132.
• Gentles L, Goranov B, Matheson E, Herriott A, Kaufmann A, Hall S, Mukhopadhyay A, Drew Y, Curtin NJ, O'Donnell RL. Exploring the frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types. Cancers 2019, 11(3), 354.
• Unterlass JE, Curtin NJ. Warburg and Krebs and related effects in cancer. Expert Reviews in Molecular Medicine 2019, 21, e4.
• Curtin NJ, Drew Y, Sharma-Saha S. Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy. Nature Reviews Clinical Oncology 2019, 16, 725–726.
• Franklin M, Gentles L, Matheson E, Bown N, Cross P, Ralte A, Gilkes-Immeson C, Bradbury A, Zanjirband M, Lunec J, Drew Y, O'Donnell R, Curtin NJ. Characterization and drug sensitivity of a novel human overian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor. Cancer Medicine 2018, 7(9), 4744-4754.
• Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GJ, Allan JM. Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances 2018, 2(10), 1157-1169.
• Berger NA, Besson VC, Boulares AH, Burkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Hasko G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sumegi B, Swanson RA, Szabo C. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. British Journal of Pharmacology 2018, 175(2), 192-222.
• Middleton FK, Pollard JR, Curtin NJ. The impact of p53 dysfunction in ATR inhibitor cytotoxicity and chemo-and radiosensitisation. Cancers 2018, 10(8), 275.
• Unterlass JE, Baslé A, Blackburn TJ, Tucker J, Turlais F, Cano C, Noble MME, Curtin NJ. Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. Oncotarget 2018, 9, 13139-13153.
• Tomassini S, Gentles L, Kirk C, Cross P, Thomas H, Wedge S, Curtin NJ, O'Donnell RL. An investigation of the effect of tissue ischaemia upon DNA damage protein markers in ovarian cancer. In: BASO - The Association for Cancer Surgery Annual Scientific Conference and the NCRI Cancer Conference. 2017, Liverpool: Elsevier.
• Zanjirband M, Curtin N, Edmondson RJ, Lunec J. Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. Oncotarget 2017, 8(41), 69779-69796.
• McCormick A, Donoghue P, Dixon M, O'Sullivan R, O'Donnell RL, Murray J, Kaufmann A, Curtin NJ, Edmondson RJ. Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib. Clinical Cancer Research 2017, 23(8), 2050-2060.
• Patterson MJ, Drew Y, Curtin NJ. PARP. In: Cancer Therapeutic Targets. New York: Springer, 2017, pp.913-934.
• Almeida GS, Bawn CM, Galler M, Wilson I, Thomas HD, Kyle S, Curtin NJ, Newell DR, Maxwell RJ. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR in Biomedicine 2017, 30(9), e3736.
• de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discovery 2017, 7(6), 620-629.
• Vormoor B, Schlosser YT, Blair H, Sharma A, Wilkinson S, Newell DR, Curtin N. Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2. Oncotarget 2017, 8(69), 113418-113430.
• Canan S, Maegley K, Curtin NJ. Strategies Employed for the Development of PARP Inhibitors. In: Methods in Molecular Biology. New York: Humana Press Inc, 2017, pp.271-297.
• Unterlass JE, Wood RJ, Basle A, Tucker J, Cano C, Noble MM, Curtin NJ. Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH). Oncotarget 2017, 8(61), 104478-104491.
• Abdulrahman GO, Curtin NJ. Targeting DNA Damage Response Pathways in Cancer. In: Samuel Chackalamannil, David Rotella and Simon Ward, ed. Comprehensive Medicinal Chemistry III. Elsevier Inc, 2017, pp.104-133.
• Rundle S, Bradbury A, Drew Y, Curtin NJ. Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers 2017, 9(5), 41.
• Shall S, Gaymes T, Farzaneh F, Curtin NJ, Mufti GJ. The use of PARP inhibitors in cancer therapy: Use as adjuvant with chemotherapy or radiotherapy, use as a single agent in susceptible patients, and techniques used to identify susceptible patients. In: Methods in Molecular Biology. New York: Humana Press Inc, 2017, pp.343-370.
• O'Donnell RL, Kaufmann A, Woodhouse L, McCormick A, Cross PA, Edmondson RJ, Curtin NJ. Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity. International Journal of Gynecological Cancer 2016, 26(6), 1004-1011.
• Alsubhi N, Middleton F, Abdel-Fatah TMA, Stephens P, Doherty R, Arora A, Moseley PM, Chan SYT, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Martin SG, Curtin NJ, Madhusudan S. Chk1 phosphorylated at serine³⁴⁵ is a predictor of early local recurrence and radio-resistance in breast cancer. Molecular Oncology 2016, 10(2), 213-223.
• Dent BM, Ogle LF, O'Donnell RL, Hayes N, Mallick U, Curtin NJ, Boddy AV, Plummer ER, Edmondson RJ, Reeves HL, May FEB, Jamieson D. High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. International Journal of Cancer 2016, 138(1), 206-216.
• Ogle LF, Orr JG, Willoughby CE, Hutton C, McPherson S, Plummer R, Boddy AV, Curtin NC, Jamieson D, Reeves HL. Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?. Journal of Hepatology 2016, 65(2), 305-313.
• Kotsopoulos IC, Begbie JA, Mukhopadhyay A, Lunec J, Curtin NJ, Kucukmetin A. IN VITRO SINGLE AGENT RUCAPARIB CYTOTOXICITY AND CISPLATIN CHEMO-POTENTIATION IN CERVICAL CANCER CELL LINES. In: 16th Biennial Meeting of the International Gynecologic Cancer Society. 2016, Lisbon, Portugal: Lippincott Williams & Wilkins, Ltd.
• Abdulrahman GO, Davison E, Matheson E, Drew Y, Curtin N, Mukhopadhyay A. Investigating PARP inhibitor sensitisation by hyperthermia and HSP90 inhibition. In: 16th Biennial Meeting of the International Gynecologic Cancer Society. 2016, Lisbon, Portugal: Lippincott Williams & Wilkins, Ltd.
• Massey AJ, Stephens P, Rawlinson R, McGurk L, Plummer R, Curtin NJ. mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition. Molecular Oncology 2016, 10(1), 101-112.
• Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. British Journal of Cancer 2016, 114(7), 723-730.
• Kotsopoulos IC, Kucukmetin A, Mukhopadhyay A, Lunec J, Curtin NJ. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis Mechanism and Potential Role for PARP Inhibitors. International Journal of Gynecological Cancer 2016, 26(4), 763-769.
• Matheson E, Salehan M, Mukhopadhyay A, Curtin NJ, Drew Y. Preclinical studies of the PARP inhibitor olaparib in combination with imatinib in BRCA stratified ovarian cancer. In: 16th Biennial Meeting of the International Gynecologic Cancer Society. 2016, Lisbon, Portugal: Lippincott Williams & Wilkins, Ltd.
• Dearman C, Sharma RA, Curtin NJ. Biomarkers for parp inhibitors. In: PARP Inhibitors for Cancer Therapy. Cham: Humana Press Inc, 2015, pp.553-579.
• Esfandiari A, Curtin NJ, Lunec J. Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner. In: AACR 106th Annual Meeting 2015. 2015, Philadelphia, Pennsylvania: American Association for Cancer Research.
• Middleton FK, Patterson MJ, Elstob CJ, Fordham S, Herriott A, Wade MA, McCormick A, Edmondson R, May FEB, Allan JM, Pollard JR, Curtin NJ. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget 2015, 6(32), 32396-32409.
• McCormick A, Donoghue P, Dixon M, O'Donnell R, Kaufmann A, Curtin N, Edmondson R. Defects in non-homologous end joining pathway in ovarian cancers results in resistance to rucaparib. In: Blair Bell Research Society. 2015, Wiley-Blackwell Publishing Ltd.
• Chen T, Middleton FK, Falcon S, Reaper PM, Pollard JR, Curtin NJ. Development of pharmacodynamic biomarkers for ATR inhibitors. Molecular Oncology 2015, 9(2), 463-472.
• Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Reeves HL. DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. Clinical Cancer Research 2015, 21(4), 925-933.
• Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NYR, Curtin NJ, Elmquist WF, Sarkaria JN. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Molecular Cancer Therapeutics 2015, 14(12), 2735-2743.
• Vormoor B, Schlosser Y, Blair H, Wilkinson S, Newell DR, Curtin N. Inhibition of DNA-Repair Enzymes (DNA-Pk and Parp) to Sensitize Ewing Sarcoma to Chemo-And Radiotherapy. In: 47th Congress of the International Society of Paediatric Oncology (SIOP). 2015, Cape Town, South Africa: Wiley-Blackwell.
• O'Donnell RL, Kaufman A, Woodhous L, McCormick A, Curtin NJ, Edmondson R. Intra- and inter-tumour heterogeneity in epithelial ovarian cancer: consequences for biomarker dependent stratification of therapies. In: Annual Meeting of the Blair Bell Research Society. 2015, Royal College of Obstetricians and Gynaecologists, London: Wiley-Blackwell.
• Wang DD, Li CZ, Sun W, Zhang SZ, Shalinsky DR, Kern KA, Curtin NJ, Sam WJ, Kirkpatrick TR, Plummer R. PARP Activity in Peripheral Blood Lymphocytes as a Predictive Biomarker for PARP Inhibition in Tumor Tissues - A Population Pharmacokinetic/Pharmacodynamic Analysis of Rucaparib. Clinical Pharmacology in Drug Development 2015, 4(2), 89-98.
• Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patternson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia. Oncotarget 2015, 6(41), 43978-43991.
• McCormick A, Nakjang S, Donoghue P, Curtin N, Edmondson R. The role of homologous recombination recovery in cisplatin and rucaparib resistance in ovarian cancer. In: 19th International Meeting of the European Society of Gynecological Oncology (ESGO 2015). 2015, Nice, France: Lippincott Williams & Wilkins.
• Unterlass JE, Aljufri N, Bex S, Cano C, Noble MEM, Curtin NJ. Towards structure-based drug design of 3-phosphoglycerate dehydrogenase inhibitors. In: AACR 106th Annual Meeting 2015. 2015, Philadelphia, PA, USA: American Association for Cancer Research.
• Abdel-Fatah TMA, Middleton FK, Arora A, Agarwal D, Chen T, Moseley PM, Perry C, Doherty R, Chan S, Green AR, Rakha E, Ball G, Ellis IO, Curtin NJ, Madhusudan S. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Molecular Oncology 2015, 9(3), 569-585.
• McCrudden CM, O'Rourke MG, Cherry KE, Yuen HF, O'Rourke D, Babur M, Telfer BA, Thomas HD, Keane P, Nambirajan T, Hagan C, O'Sullivan JM, Shaw C, Williams KJ, Curtin NJ, Hirst DG, Robson T. Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself. PLoS One 2015, 10(2).
• Patterson MJ, Sutton RJ, Forrest I, Sharrock R, Lane M, Kaufmann A, O'Donnell R, Edmondson R, Wilson BT, Curtin N. Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples. British Journal of Cancer 2014, 111(1), 94-100.
• Ogle L, Jamieson D, O'Donnell R, Dent B, Boddy A, Curtin N, Plummer R, Reeves H, Clinical and Translational Group. Detection of circulating tumour cells (CTCS) in hepatocellular (HCC) cancer patients using the ImageStream^x. In: The International Liver Congress 2014: 49th Annual Meeting of the European Association for the Study of the Liver. 2014, London: Elsevier BV.
• Ciszewski WM, Tavecchio M, Dastych J, Curtin NJ. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast Cancer Research and Treatment 2014, 143(1), 47-55.
• Veuger S, Curtin NJ. Inhibition of DNA Repair as a Therapeutic Target. In: Cancer Drug Design and Discovery. London: Academic Press, 2014, pp.193-237.
• Curtin N. PARP inhibitors for anticancer therapy. Biochemical Society Transactions 2014, 42(1), 82-88.
• Curtin NJ. PARP inhibitors target ATM+p53-defective gastric cancer. Cell Cycle 2014, 13(20), 3161-3162.
• Vormoor B, Curtin NJ. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma. Current Opinion in Oncology 2014, 26(4), 428-433.
• Znojek P, Willmore E, Curtin NJ. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. British Journal of Cancer 2014, 111(7), 1319-1326.
• O'Donnell RL, McCormick A, Mukhopadhyay A, Woodhouse LC, Moat M, Grundy A, Dixon M, Kaufmann A, Soohoo S, Elattar A, Curtin NJ, Edmondson RJ. The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis. PLoS ONE 2014, 9(3), e90604.
• Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. British Journal of Cancer 2014, 110, 1977-1984.
• Cano C, Saravanan K, Bailey C, Bardos J, Curtin NJ, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Menear KA, Newell DR, Richardson CJ, Shea K, Smith GCM, Thommes P, Ting A, Griffin RJ. 1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK PI3-K Inhibitory Activity. Journal of Medicinal Chemistry 2013, 56(16), 6386-6401.
• Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, Abbattista A, Gallo J, Calvert H. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemotherapy and Pharmacology 2013, 71(5), 1191-1199.
• Middleton FK, Curtin NJ. ATR as a therapeutic target. In: Advances in DNA Repair in Cancer Therapy. New York: Springer, 2013, pp.211-228.
• Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJR, Cox A, Curtin NJ, Dekker LV, Silva ID, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans DG, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JMW, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin LA, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JPB, O'Connor R, Palmieri C, Pharoah PDP, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt ANJ, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research 2013, 15(5), 1-37.
• Curtin NJ. Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. British Journal of Pharmacology 2013, 169(8), 1745-1765.
• Gaymes TJ, Mohamedali AM, Patterson M, Matto N, Smith A, Kulasekararaj A, Chelliah R, Curtin N, Farzaneh F, Shall S, Mufti GJ. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica 2013, 98(9), 1397-1406.
• McCormick A, Dixon M, ODonnell R, Curtin NJ, Edmondson RJ. Ovarian cancers harbor defects in nonhomologous end joining resulting in error prone repair and resistance to rucaparib. In: CLINICAL CANCER RESEARCH. 2013, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH.
• Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NMB, Lau A, Newell DR, Curtin NJ. Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer. Molecular Cancer Therapeutics 2013, 12(6), 959-967.
• Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond. Molecular Aspects of Medicine 2013, 34(6), 1217-1256.
• Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson C, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L, Griffin RJ, Menear KA, Slade A, Thommes P, Martin NMB, Newell DR, Smith GCM, Curtin NJ. Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K. Molecular Cancer Therapeutics 2012, 11(8), 1789-1798.
• Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, Edmondson RJ. Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival. Cancer Research 2012, 72(22), 5675-5682.
• Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, Edmondson RJ. Defective homologous recombination in human cancers. Cancer Treatment Reviews 2012, 38(2), 89-100.
• Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nature Reviews Cancer 2012, 12(12), 801-817.
• Tavecchio M, Munck JM, Cano C, Newell DR, Curtin NJ. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemotherapy and Pharmacology 2012, 69(1), 155-164.
• Curtin NJ. Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors. Drug Discovery Today: Disease Models 2012, 9(2), e51-e58.
• Chen T, Stephens PA, Middleton FK, Curtin NJ. Targeting the S and G2 checkpoint to treat cancer. Drug Discovery Today 2012, 17(5-6), 194-202.
• Shall S, Gaymes T, Farzaneh F, Curtin N, Mufti GJ. The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients. In: Tulin, A, ed. Poly(ADP-ribose) Polymerase: Methods and Protocols. New York, USA: Humana Press, Inc, 2012, pp.239-66.
• Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G. Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast 2012, 21(1), 20-26.
• Spagnolo L, Barbeau J, Curtin NJ, Morris EP, Pearl LH. Visualization of a DNA-PK/PARP1 complex. Nucleic Acids Research 2012, 40(9), 4168-4177.
• Johnson N, Li YC, Walton ZE, Cheng KA, Li DA, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature Medicine 2011, 17(7), 875-882.
• Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, Cliby WA, Sarkaria J, Beale G, Edmondson RJ, Curtin NJ. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. British Journal of Cancer 2011, 105(3), 372-381.
• Saravanan K, Barlow HC, Barton M, Calvert AH, Golding BT, Newell DR, Northen JS, Curtin NJ, Thomas HD, Griffin RJ. Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α₁-Acid Glycoprotein. Journal of Medicinal Chemistry 2011, 54(6), 1847-1859.
• Mukhopadhyay A, Curtin N, Plummer R, Edmondson RJ. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY 2011, 118(4), 429-432.
• Mukhopadhyay A, Curtin NJ, Plummer ER, Edmondson RJ. PARP Inhibitors And Epithelial Ovarian Cancer: An Approach To Targeted Chemotherapy And Personalized Medicine. BJOG 2011, 118(4), 429-432.
• Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, Curtin NJ. Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochemical Journal 2011, 436(3), 671–679.
• Thomas HD, Wang LZ, Roche C, Bentley J, Cheng YZ, Hardcastle IR, Golding BT, Griffin RJ, Curtin NJ, Newell DR. Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. European Journal of Cancer 2011, 47(13), 2052-2059.
• Canan S, Maegley K, Curtin N. Strategies employed for the development of PARP inhibitors. In: Virag, A, ed. Poly(ADP-ribose) Polymerase: Methods and Protocols. New York, USA: Humana Press, Inc, 2011, pp.463-89.
• Shaheen FS, Znojek P, Fisher A, Webster M, Plummer R, Gaughan L, Smith GCM, Leung HY, Curtin NJ, Robson CN. Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer. PLoS One 2011, 6(5), e20311.
• Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ, Williams KJ. The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice. Molecular Cancer Therapeutics 2011, 10(12), 2320-2329.
• Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Therapeutic Advances in Medical Oncology 2011, 3(6), 257-267.
• Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. British Journal of Cancer 2011, 105(8), 1114-1122.
• Drew Y, Mulligan EA, Vong W, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ. Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2. Journal of the National Cancer Institute 2011, 103(4), 334-346.
• Issaeva N, Thomas HD, Djurenovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T. 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. Cancer Research 2010, 70(15), 6268-6276.
• Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British Journal of Cancer 2010, 103(10), 1588-1596.
• Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, Curtin NJ. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clinical Cancer Research 2010, 16(8), 2344-2351.
• Cano C, Barbeau OR, Bailey C, Cockcroft XL, Curtin NJ, Duggan H, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Knights C, Menear KA, Newell DR, Richardson CJ, Smith GC, Spittle B, Griffin RJ. DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype. Journal of Medicinal Chemistry 2010, 53(24), 8498-8507.
• Zaremba T, Thomas H, Cole M, Plummer ER, Curtin NJ. Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials. Cancer Chemotherapy and Pharmacology 2010, 66(4), 807-812.
• Johnson N, Bentley J, Wang LZ, Newell DR, Robson CN, Shapiro GI, Curtin NJ. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. British Journal of Cancer 2010, 102(2), 342-350.
• Marchetti F, Cano C, Curtin NJ, Golding BT, Griffin RJ, Haggerty K, Newell DR, Parsons RJ, Payne SL, Wang LZ, Hardcastle IR. Synthesis and biological evaluation of 5-substituted O⁴-alkylpyrimidines as CDK2 inhibitors. Organic & Biomolecular Chemistry 2010, 8(10), 2397-2407.
• Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Molecular Cancer Therapeutics 2009, 8(2), 407-414.
• Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ, Clifford SC. Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma. Clinical Cancer Research 2009, 15(4), 1241-1249.
• Mitchell J, Smith GCM, Curtin NJ. Poly(ADP-Ribose) Polymerase-1 and DNA-Dependent Protein Kinase Have Equivalent Roles in Double Strand Break Repair Following Ionizing Radiation. International Journal of Radiation: Oncology - Biology - Physics 2009, 75(5), 1520-1527.
• Zaremba T, Ketzer P, Cole M, Coulthard S, Plummer ER, Curtin NJ. Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. British Journal of Cancer 2009, 101(2), 256-262.
• Thomas HD, Saravanan K, Wang LZ, Lin MJ, Northen JS, Barlow H, Barton M, Newell DR, Griffin RJ, Golding BT, Curtin NJ. Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity. Molecular Cancer Therapeutics 2009, 8(7), 1828-1837.
• Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, Kyle S, Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ. Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?. Clinical Cancer Research 2009, 15(19), 6106-6112.
• Murr M, Cano C, Golding BT, Hardcastle IR, Hummersome M, Frigerio M, Curtin NJ, Menear K, Richardson C, Smith G, Griffin R. 8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK). Bioorganic and Medicinal Chemistry Letters 2008, 18(17), 4885-4890.
• Plummer ER, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin NJ, Boddy AV, McHugh P, Newell DR, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert AH. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clinical Cancer Research 2008, 14(23), 7917-7923.
• Scrace SF, Kierstan P, Borgognoni J, Wang LZ, Denny S, Wayne J, Bentley C, Cansfield AD, Jackson PS, Lockie AM, Curtin NJ, Newell DR, Williamson DS, Moore JD. Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked. Cell Cycle 2008, 7(24), 3898-3907.
• Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anti-Cancer Agents in Medicinal Chemistry 2007, 7(5), 515-523.
• Thomas HD, Calabrese CR, Batey M, Canan S, Hostomsky Z, Kyle S, Maegley K, Newell DR, Skalitzky D, Wang L, Webber SE, Curtin NJ. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Molecular Cancer Therapeutics 2007, 6(3), 945-956.
• Hollick J, Rigoreau L, Cano-Soumillac C, Cockcroft X, Curtin NJ, Frigerio M, Golding BT, Guiard S, Hardcastle IR, Hickson I, Hummersone M, Menear K, Martin N, Matthews I, Newell DR, Ord R, Richardson C, Smith G, Griffin RJ. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase. Journal of Medicinal Chemistry 2007, 50(8), 1958-1972.
• Marchetti F, Sayle KL, Bentley J, Clegg W, Curtin NJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Harrington RW, Mesguiche V, Newell DR, Noble MEM, Parsons RJ, Pratt DJ, Wang L, Hardcastle IR, Mesguiche V, Newell DR, Noble MEM, Parsons RJ, Pratt DJ, Wang L, Hardcastle IR. Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinase 2. Organic and Biomolecular Chemistry 2007, 5(10), 1577-1585.
• Rigas AC, Robson CN, Curtin NJ. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene 2007, 26(55), 7611-7619.
• Curtin NJ. Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opinion on Therapeutic Targets 2007, 11(6), 783-799.
• Zhao Y, Thomas HD, Batey M, Cowell I, Richardson C, Griffin RJ, Calvert AH, Newell DR, Smith G, Curtin NJ. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Research 2006, 66(10), 5354-5362.
• Griffin RJ, Henderson A, Curtin NJ, Echalier A, Endicott J, Hardcastle IR, Newell DR, Noble M, Wang L, Golding BT. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination. Journal of the American Chemical Society 2006, 128(18), 6012-6013.
• Hardcastle I, Cockcroft X, Curtin NJ, El-Murr M, Leahy JJJ, Stockley M, Golding BT, Rigoreau L, Richardson C, Smith G, Griffin RJ. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. Journal of Medicinal Chemistry 2005, 48(24), 7829-7846.
• Fishel M, Newell D, Griffin R, Davison R, Wang L, Curtin NJ, Zuhowski E, Kasza K, Egorin M, Moschel R, Dolan M. Effect of cell cycle inhibition on cisplatin-induced cytotoxicity. Journal of Pharmacology and Experimental Therapeutics 2005, 312(1), 206-213.
• Hardcastle I, Ahmed S, Atkins H, Calvert AH, Curtin NJ, Farnie G, Golding BT, Griffin R, Guyenne S, Hutton C, Källblad P, Kemp S, Kitching M, Newell D, Norbedo S, Northen J, Reid R, Saravanan K, Willems H, Lunec J. Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. Bioorganic and Medicinal Chemistry Letters 2005, 15(5), 1515-1520.
• Curtin NJ. PARP inhibitors for cancer therapy. Expert Reviews in Molecular Medicine 2005, 7(4), 1-20.
• Curtin NJ. PARP inhibitors for cancer therapy. Expert Reviews in Molecular Medicine 2005, 7(4), 1-20.
• Pennati M, Campbell AJ, Curto M, Binda M, Cheng Y, Wang L, Curtin NJ, Golding BT, Griffin RJ, Hardcastle IR, Henderson A, Zaffaroni N, Newell DR. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: A possible role for survivin down-regulation. Molecular Cancer Therapeutics 2005, 4(9), 1328-1337.
• Bryant H, Schultz N, Thomas HD, Parker K, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035), 913-917.
• Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, Margison GP, McGown G, Thorncroft M, Watson AJ, Boddy AV, Calvert AH, Harris AL, Newell DR, Curtin NJ. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O⁶-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clinical Cancer Research 2005, 11(9), 3402-3409.
• Smith LM, Willmore E, Austin C, Curtin NJ. The novel poly(ADP-ribose) polymerase inhibitor, AG14361 sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clinical Cancer Research 2005, 11(23), 8449-8457.
• Calabrese C, Almassy R, Barton S, Batey M, Calvert AH, Canan-Koch S, Durkacz B, Hostomsky Z, Kumpf R, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford I, Skalitzky D, Thomas HD, Wang L, Webber S, William K, Curtin NJ. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. Journal of the National Cancer Institute 2004, 96(1), 56-67.
• Tikhe J, Webber S, Hostomsky Z, Maegley K, Ekkers A, Li J, Yu X, Almassy R, Kumpf R, Boritzki T, Zhang C, Calabrese C, Curtin NJ, Kyle S, Thomas HD, Wang L, Calvert AH, Golding B, Griffin RJ, Newell DR. Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. Journal of Medicinal Chemistry 2004, 47(22), 5467-5481.
• Veuger SJ, Curtin NJ, Smith GCM, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004, 23(44), 7322–7329.
• Veuger SJ, Curtin NJ, Smith G, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004, 23(44), 7322-7329.
• Hickson, I., Zhao, Y., Richardson, C., Green, S., Martin, N., Orr, A., Reaper, P., Jackson, S., Curtin, N.J., Smith, G. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Research 2004, 64(24), 9152-9159.
• Hardcastle IR, Arris CE, Bentley J, Boyle FT, Chen Y, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Jewsbury, P., Menyerol, J., Mesguiche, V., Newell, D.R., Noble, M., Pratt, D., Wang, L., Whitfield, H.J. N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2. Journal of Medicinal Chemistry 2004, 47(15), 3710-3722.
• Curtin NJ, Wang L, Yiakouvaki A, Kyle S, Arris C, Canan-Koch S, Webber S, Durkacz BW, Calvert AH, Hostomsky Z, Newell DR. Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells. Clinical Cancer Research 2004, 10(3), 881-889.
• White, A., Curtin, N.J., Eastman, B., Golding, B.T., Hostomsky, Z., Kyle,S., Li, J., Maegley, K., Skalitzky, D., Webber, S., Yu, X., Griffin, R.J. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorganic and Medicinal Chemistry Letters 2004, 14(10), 2433-2437.
• Curtin, N., Barlow, H., Bowman, K., Calvert, A. H., Davison, R., Golding, B., Huang, B., Loughlin, P., Newell, D., Smith, P., Griffin, R. Resistance-modifying agents. 11. Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to α₁-acid glycoprotein. Journal of Medicinal Chemistry 2004, 47(20), 4905-4922.
• Mesguiche, V, Parsons, R.J., Arris, C.E., Bentley, J., Boyle, F., Curtin, N.J., Davies, T.G., Endicott, J., Gibson, A., Golding, B., Griffin, R.J., Jewsbury, P., Johnson, L.N., Newell, D.R., Noble, M.E.M., Wang, L., Hardcastle, I.R. 4-Alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 2. Bioorganic and Medicinal Chemistry Letters 2003, 13(2), 217-222.
• Calabrese C, Batey M, Thomas HD, Durkacz B, Wang L, Kyle S, Skalitzky D, Li J, Zhang C, Boritzki T, Maegley K, Calvert AH, Hostomsky Z, Newell DR, Curtin NJ. Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies. Clinical Cancer Research 2003, 9(7), 2711-2718.
• Veuger, S., Curtin, N.J., Richardson, C., Smith, G., Durkacz, B.W. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Research 2003, 63(18), 6008-6015.
• Sayle, K., Bentley, J., Boyle, F., Calvert, A. H., Cheng, Y., Curtin, N. J., Endicott, J., Golding, B., Hardcastle, I., Jewsbury, P., Mesguiche, V., Newell, D. R., Noble, M., Parsons, R., Pratt, D., Wang, L., Griffin, R. J. Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorganic and Medicinal Chemistry Letters 2003, 13(18), 3079-3082.
• Skalitzky, D., Marakovits, J., Maegley, K., Ekker, A., Yu, X., Hostomsky, Z., Webber, S., Eastman, B., Almassy, R., Li, J., Curtin, N. J., Newell, D. R., Calvert, A. H., Griffin, R. J., Golding, B. T. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. Journal of Medicinal Chemistry 2003, 46(2), 210-213.
• Northen J, Boyle F, Clegg W, Curtin NJ, Edwards A, Griffin R, Golding B. Controlled stepwise conversion of 2,4,6,8-tetrachloropyrimido-[5,4-d ]pyrimidine into 2,4,6,8-tetrasubstituted pyrimido[5,4-d]pyrimidines. Journal of the Chemical Society. Perkin Transactions 1 2002, 2(1), 108-115.
• Monks, N., Blakey, D., East, S., Dowell, R., Calvete, J., Curtin, N.J., Arris, C.E., Newell, D.R. DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767. European Journal of Cancer 2002, 38(11), 1543-1552.
• Koch SSC, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li JK, Yu XH, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure. Journal of Medicinal Chemistry 2002, 45(23), 4961-4974.
• Gibson A, Arris CE, Bentley J, Boyle F, Curtin NJ, Davies T, Endicott J, Golding BT, Grant S, Griffin R, Jewsbury, P., Johnson, L., Mesguiche, V., Newell, D.R., Noble, M., Tucker, J., Whitfield, H.J. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O6-substituted guanine derivatives. Journal of Medicinal Chemistry 2002, 45(16), 3381-3393.
• Davies T, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott J, Gibson A, Golding BT, Griffin RJ, Hardcastle IR, Jewsbury, P., Johnson, L., Mesguiche, V., Newell, D.R., Noble, M., Tucker, J.A., Wang, L., Whitfield, H.J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Structural Biology 2002, 9(10), 745-749.
• Lu X, Errington J, Curtin NJ, Lunec J, Newell DR. The impact of p53 status on cellular sensitivity to antifolate drugs. Clinical Cancer Research 2001, 7(7), 2114-2123.
• Bowman, K. J., Newell, D. R., Calvert, A. H., Curtin, N. J. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. British Journal of Cancer 2001, 84(1), 106-112.
• Marshman, E., Taylor, G., Thomas, H., Newell, D.R., Curtin, N.J. Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole. Biochemical Pharmacology 2001, 61(4), 477-484.
• Smith PG, Thomas HD, Barlow HC, Griffin RJ, Golding BT, Calvert AH, Newell DR, Curtin NJ. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. Clinical Cancer Research 2001, 7(7), 2105-2113.
• Monks, N., Blakey,D., Curtin, N.J., East, S., Heuze, A., Newell, D.R. Induction of apoptosis by the ADEPT agent ZD2767: Comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue. British Journal of Cancer 2001, 85(5), 764-771.
• Curtin, N.J., Hughes, A.N. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncology 2001, 2(5), 298-306.
• Lu, X., Errington, J., Chen, V., Curtin, N. J., Boddy, A. V., Newell, D. R. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clinical Cancer Research 2000, 6(1), 271-277.
• Monks, N., Calvete, J., Curtin, N.J., Blakey, D., East, S., Newell, D.R. Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT). British Journal of Cancer 2000, 83(2), 267-269.
• Smith, P., Marshman, E., Newell, D.R., Curtin, N.J. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport. British Journal of Cancer 2000, 82(4), 924-930.
• Arris, C. E., Boyle, F., Calvert, A. H., Curtin, N. J., Endicott, J. A., Garman, E. F., Gibson, A. E., Golding, B. T., Grant, S., Griffin, R. J., Jewsbury, P., Johnson, L., Lawrie, A., Newell, D. R., Noble, M., Sausville, E., Schultz, R., Yu, W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Journal of Medicinal Chemistry 2000, 43(15), 2797-2804.
• Delaney, C.A., Wang, L., Kyle, S., White, A.W., Calvert, A.H., Curtin, N.J., Durkacz, B.W., Hostomsky, Z, Newell, D.R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clinical Cancer Research 2000, 6(7), 2860-2867.
• Griffin, R. J., Arris, C. E., Bleasdale, C. , Boyle, F., Calvert, A. H., Curtin, N. J., Dalby, C., Kanugula, S., Lembicz, N., Newell, D. R., Pegg, A., Golding, B. T. Resistance-modifying agents. 8. Inhibition of O⁶-alkylguanine-DNA alkyltransferase by O⁶-alkenyl-, O⁶-cycloalkenyl-, and O⁶-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O⁶-(1-cyclopentenylmethyl) guanine. Journal of Medicinal Chemistry 2000, 43(22), 4071-4083.
• White, A.W., Almassy, R., Calvert, A.H., Curtin, N.J., Griffin, R.J., Hostomsky, Z., Maegley, K., Newell, D.R., Srinivasan, S, Golding, B.T. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. Journal of Medicinal Chemistry 2000, 43(22), 4084-4097.
• Barlow, H. C., Bowman, K. J., Curtin, N. J., Calvert, A. H., Golding, B. T., Huang, B., Loughlin, P. J., Newell, D. R., Smith, P. G., Griffin, R. J. Resistance-modifying agents. Part 7: 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP). Bioorganic and Medicinal Chemistry Letters 2000, 10(6), 585-589.
• Bentley J, Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury PJ, Johnson LN, Noble MEM, Newell DR. Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors. Clinical Cancer Research 2000, 6, 328.
• Curtin, N.J., Turner, D.P. Dipyridamole-mediated reversal of multidrug resistance in MRP over- expressing human lung carcinoma cells in vitro. European Journal of Cancer 1999, 35(6), 1020-1026.
• Curtin, N.J., Bowman, K., Turner, R., Huang, B., Loughlin, P., Calvert, A.H., Golding, B.T., Griffin, R.J., Newell, D.R. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α1-acid glycoprotein binding. British Journal of Cancer 1999, 80(11), 1738-1746.
• Smith, P.G., Marshman, E., Calvert, A., Newell, D.R., Curtin, N.J. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines. Seminars in Oncology 1999, 26(2), 63-67.
• Marshman, E., Newell, D.R., Calvert, A.H., Dickinson, A., Patel, H., Campbell, F., Curtin, N.J. Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro. Clinical Cancer Research 1998, 4(11), 2895-2902.
• Bowman, J., White, A.W., Golding, B.T., Griffin, R.J., Curtin, N.J. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. British Journal of Cancer 1998, 78(10), 1269-1277.
• Griffin, R. J., Srinivasan, S., Bowman, K., Calvert, A. H., Curtin, N. J., Newell, D. R., Pemberton, L. C., Golding, B. T. Resistance-modifying agents. 5.1 Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). Journal of Medicinal Chemistry 1998, 41(26), 5247-5256.
• Turner, R., Aherne, G., Curtin, N.J. Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage. British Journal of Cancer 1997, 76(10), 1300-1307.
• Turner, R., Curtin, N.J. Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cells. British Journal of Cancer 1996, 73(7), 856-860.
• Griffin, R.J., Srinivasan, S., White, A.W., Bowman, K., Calvert, A.H., Curtin, N.J., Newell, D.R., Golding, B.T. Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme Poly(ADP-ribose)polymerase. Pharmaceutical Sciences 1996, 2(1), 43-47.
• Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. The Role of Inhibitors of Poly(Adp-Ribose) Polymerase as Resistance-Modifying Agents in Cancer-Therapy. Biochimie 1995, 77(6), 408-422.
• Arris, C. E., Bleasdale, C., Calvert, A. H., Curtin, N. J., Dalby, C., Golding, B. T., Griffin, R. J., Lunn, J. M., Major, G. N., Newell, D. R. Probing the active site and mechanism of action of O-6-methylguanine-DNA methyltransferase with substrate-analogs to (O-6-substituted guanines). Anti-Cancer Drug Design 1994, 9(5), 401-408.
• Curtin, N. J., Harris, A. L., Aherne, G. W. Mechanism of cell-death following thymidylate synthase inhibition - 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth-inhibition following exposure to CB3717 and dipyridamole. Cancer Research 1991, 51(9), 2346-2352.
• Curtin NJ, Newell DR, Harris AL. Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole. Biochemical Pharmacology 1989, 38(19), 3281-8.
• Piall, E. M., Curtin, N. J., Aherne, G. W., Harris, A. L., Marks, V. The quantitation by radioimmunoassay of 2'-deoxyuridine 5'-triphosphate in extracts of thymidylate synthase-inhabited cells. Analytical Biochemistry 1989, 177(2), 347-352.
• Curtin NJ, Harris AL. Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells. Biochemical Pharmacology 1988, 37(11), 2113-20.
• Bassendine MF, Curtin NJ, Loose H, Harris AL, James OF. Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study. Journal of Hepatology 1987, 4(3), 349-56.
• Curtin NJ, Harris AL, James OFW, Bassendine MF. Inhibition of the growth of human hepatocellular-carcinoma invitro and in athymic mice by a quinazoline inhibitor of thymidylate suntjase, CB3717. British Journal of Cancer 1986, 53(3), 361-368.
• Curtin NJ, Snell K. Enzymic retrodifferentiation during hepatocarcinogenesis and liver regeneration in rats in vivo. British Journal of Cancer 1983, 48(4), 495-505.
• Margison GP, Curtin NJ, Snell K, Craig AW. Effect of chronic N,N-diethylnitrosamine on the excision of O⁶-ethylguanine from rat liver DNA. British Journal of Cancer 1979, 40(5), 809-813.